Pharmadrug Inc.
PHRX
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.16% | -66.01% | -92.43% | -91.36% | -91.48% |
| Depreciation & Amortization | 0.00% | -1.91% | -23.40% | -4.50% | 26.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.13% | -68.24% | -81.59% | -81.60% | -85.79% |
| Operating Income | 13.13% | 68.24% | 81.59% | 81.60% | 85.79% |
| Income Before Tax | -13.71% | 52.03% | 97.98% | 97.34% | 96.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.71% | 52.03% | 97.83% | 97.14% | 96.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -19.58% | -40.37% | -60.51% | -57.41% | -51.29% |
| Net Income | -17.99% | 53.22% | 98.19% | 97.50% | 97.12% |
| EBIT | 13.13% | 68.24% | 81.59% | 81.60% | 85.79% |
| EBITDA | 16.70% | 73.92% | 85.08% | 84.86% | 88.65% |
| EPS Basic | -3.57% | 59.02% | 98.76% | 98.26% | 97.96% |
| Normalized Basic EPS | -10.00% | 48.72% | 84.88% | 83.00% | 84.13% |
| EPS Diluted | -3.57% | 59.02% | 98.76% | 98.26% | 97.96% |
| Normalized Diluted EPS | -10.00% | 48.72% | 84.88% | 83.00% | 84.13% |
| Average Basic Shares Outstanding | 9.25% | 6.21% | 15.82% | 33.87% | 55.54% |
| Average Diluted Shares Outstanding | 9.25% | 6.21% | 15.82% | 33.87% | 55.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |